Supernus Pharmaceuticals, Inc. $SUPN Stock Position Raised by Cubist Systematic Strategies LLC

Key Points

• Cubist Systematic Strategies LLC increased its stake in Supernus Pharmaceuticals by 7.1%, acquiring an additional 9,967 shares, and now holds a total of 149,489 shares valued at approximately $4.9 million.
• CEO Jack A. Khattar sold 140,000 shares of Supernus stock for about $5.88 million, resulting in an 11.96% decrease in his ownership position.
• Supernus Pharmaceuticals' stock received several analyst upgrades, with Cantor Fitzgerald raising its target price from $42.00 to $46.00 and issuing an "overweight" rating.

Cubist Systematic Strategies LLC lifted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 7.1% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 149,489 shares of the specialty pharmaceutical company's stock after acquiring an additional 9,967 shares during the quarter. Cubist Systematic Strategies LLC owned approximately 0.27% of Supernus Pharmaceuticals worth $4,896,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Raiffeisen Bank International AG purchased a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at approximately $25,000. Financial Management Professionals Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the 1st quarter valued at approximately $30,000. Versant Capital Management Inc lifted its position in shares of Supernus Pharmaceuticals by 6,931.3% in the 1st quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock valued at $37,000 after acquiring an additional 1,109 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Supernus Pharmaceuticals in the 1st quarter valued at approximately $41,000. Finally, GF Fund Management CO. LTD. purchased a new stake in Supernus Pharmaceuticals in the 4th quarter worth approximately $42,000.

Insiders Place Their Bets

In related news, CEO Jack A. Khattar sold 140,000 shares of the firm's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $42.02, for a total value of $5,882,800.00. Following the transaction, the chief executive officer directly owned 1,030,183 shares in the company, valued at approximately $43,288,289.66. This trade represents a 11.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Frederick M. Hudson sold 7,457 shares of the firm's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $42.26, for a total transaction of $315,132.82. Following the completion of the transaction, the director owned 46,307 shares in the company, valued at $1,956,933.82. The trade was a 13.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 179,606 shares of company stock worth $7,617,005 in the last ninety days. 8.80% of the stock is owned by insiders.

Supernus Pharmaceuticals Trading Up 0.9%

Supernus Pharmaceuticals stock opened at $44.93 on Thursday. The company has a market capitalization of $2.52 billion, a P/E ratio of 39.07 and a beta of 0.79. The firm's fifty day simple moving average is $37.43 and its 200-day simple moving average is $34.06. Supernus Pharmaceuticals, Inc. has a 1-year low of $29.16 and a 1-year high of $45.94.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on SUPN shares. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Cantor Fitzgerald increased their target price on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 6th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 19th. Finally, Piper Sandler increased their target price on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a "neutral" rating in a research report on Friday, August 29th. Two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $43.00.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.